Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits by MATT RICHTEL and ANDREW POLLACK


By MATT RICHTEL and ANDREW POLLACK

Public funding is backing a new immunotherapy treatment, but the bulk of any profits will go to a private company. So are taxpayers getting a good deal?

Published: December 18, 2016 at 07:00PM

from NYT Health http://ift.tt/2hjPPDW
via IFTTT

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s